Cidara Therapeutics (CDTX) Profit After Tax: 2017-2025
Historic Profit After Tax for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.2 million.
- Cidara Therapeutics' Profit After Tax fell 420.69% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 46.80%. This contributed to the annual value of -$170.3 million for FY2024, which is 578.99% down from last year.
- Per Cidara Therapeutics' latest filing, its Profit After Tax stood at -$83.2 million for Q3 2025, which was down 223.64% from -$25.7 million recorded in Q2 2025.
- Cidara Therapeutics' Profit After Tax's 5-year high stood at $14.2 million during Q3 2022, with a 5-year trough of -$94.2 million in Q2 2024.
- In the last 3 years, Cidara Therapeutics' Profit After Tax had a median value of -$16.0 million in 2024 and averaged -$30.0 million.
- In the last 5 years, Cidara Therapeutics' Profit After Tax surged by 178.78% in 2022 and then crashed by 876.67% in 2024.
- Quarterly analysis of 5 years shows Cidara Therapeutics' Profit After Tax stood at -$16.8 million in 2021, then grew by 19.08% to -$13.6 million in 2022, then skyrocketed by 60.56% to -$5.4 million in 2023, then slumped by 876.67% to -$52.4 million in 2024, then crashed by 420.69% to -$83.2 million in 2025.
- Its Profit After Tax stands at -$83.2 million for Q3 2025, versus -$25.7 million for Q2 2025 and -$23.5 million for Q1 2025.